Svenska
Glossary
Search
Latest News
Upcoming Events
Juni 22, 2010
NeuroNovas läkemedelskandidat sNN0029 för ALS får särläkemedelsstatus av amerikanska läkemedelsmyndigheten FDA
June 22, 2010
NeuroNova´s drug candidate sNN0029 for ALS/Lou Gehrig´s disease receives orphan drug designation by the FDA
Sept 22-25, 2010. European Society for Sterotactic and Functional Neurosurgery, Athens, Greece
Sept 25-28, 2010. European Federation of Neurological Societies (EFNS), Geneva, Switzerland.
Sept 28- Oct 1, 2010. World Parkinson Congress 2010, Glasgow, Scotland.
Nov 13- 17, 2010. Society for Neuroscience (SFN), San Diego, California, USA.
© NeuroNova AB, Sweden, Tel: +46 (0)8 786 0900, Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Sitemap
Site policy
Site last updated: Tuesday 22 June 2010
Project Pipeline
Project
Indication
Pre-clin.
IND
Phase I/II
Phase II
Phase III
sNN0029
ALS
sNN0031
Parkinson's disease
More about our Projects
Business Development
NeuroNova’s business strategy centers on developing novel therapeutic products based on neurogenesis in areas of high unmet medical need in neurodegenerative diseases.
More about business development.